In 46 patients with advanced stage BRAF-V600E mutated NSCLC at data cutoff, 25 patients received chemotherapy in the first-line (19 with pemetrexed-contained regimen, 5 with paclitaxel-contained regimen, 1 with gemcitabine-contained regimen), while only 16 patients received anti-BRAF targeted therapy as the first-line choice (9 with vemurafenib, 2 with dabrafenib, 5 with dabrafenib plus trametinib). This evidence concerns the gene BRAF and non-small cell lung carcinoma.